• All
  • Financials
  • Insiders
Webull provides the latest Anavex Life (AVXL) stock and general news. This information may help you make smarter investment decisions.
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.